Firebrick Pharma (ASX:FRE) has executed a consulting agreement with Keith Shortall, a former senior executive of Johnson & Johnson Consumer Health Asia-Pacific.
The primary goal of the Agreement is to establish pharmacy distribution for Nasodine in Singapore. Secondary objectives include evaluating potential distribution to other markets in Southeast Asia and partnership opportunities in the region.
Keith Shortall was recently (2022-2023) Head of Customer Experience for J&J Consumer Health APAC, based in Singapore, and previously (2018-2022) Managing Director North Asia for J&J Consumer Health APAC. He has extensive Asia Pacific (APAC) experience, operating in more than 20 markets across APAC in his 15 years of working and living in APAC countries.
“Keith’s expertise in the distribution, marketing and partnering of consumer health products in the region is an outstanding asset for Firebrick,” said Firebrick Executive Chairman, Dr Peter Molloy. “We are excited about what he can achieve for us in Singapore and across the region.”
The Options will vest upon achievement of the following performance milestone:
- Distribution of Nasodine Nasal Spray in chain and/or independent pharmacy in Singapore on or before 30 June 2025.
The Terms and Conditions of the Options are attached.
